Eli Lilly (LLY) Q2 2025 earnings report

Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company raised its fiscal 2025 sales guidance to $60 billion to $62 billion, from a previous outlook of $58 billion to $61 billion on underlying strength across its business….

Read More

Trump administration to pilot covering obesity drugs

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. For…

Read More

Palantir, Berkshire Hathaway, Disney, McDonald’s

CNBC’s Jim Cramer walked investors through another week of earnings season, honing in on reports from Palantir, Berkshire Hathaway, Disney and Eli Lilly. “We’re still in earnings Hades, but at least it’s getting a little cooler out there,” he said. “That’s right, we’ve now gotten over the hump of the big-time growth stocks, the hyperscalers,…

Read More